Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jun;17(3):235-40.
doi: 10.1097/MOT.0b013e3283534ec9.

Cellular therapy and bioartificial approaches to liver replacement

Affiliations
Review

Cellular therapy and bioartificial approaches to liver replacement

Jason A Wertheim et al. Curr Opin Organ Transplant. 2012 Jun.

Abstract

Purpose of review: The success of liver transplantation has increased over the past 20 years due to improved immunosuppressive medications, surgical technique and donor-recipient selection. To date, the number of patients waiting for a liver transplant exceeds the number of transplants performed yearly by over a 2 : 1 ratio. Despite efforts to expand the donor pool, mortality of patients waiting for a liver remains high due to the shortage of donor organs. Herein, we discuss options for liver replacement that are currently under development.

Recent findings: Extracorporeal bioactive liver perfusion devices were investigated in the late 1990s and preliminarily demonstrated safety but failed to show clinical efficacy. Current research is ongoing, but the focus has shifted to xenotransplantation of whole organs, organ engineering and cell transplantation. These new modalities are limited to small and large animal studies and each present unique advantages and limitations.

Summary: Discovery of new sources of organs or cells to replace a damaged liver may be the only long-term solution to provide definitive therapy to all patients who require transplantation. The past 2 years have seen notable achievements in xenotransplantation, tissue engineering and cell transplantation. Though challenges remain, now identified, they may be readily solved.

PubMed Disclaimer

References

    1. Wertheim JA, Petrowsky H, Saab S, et al. Major challenges limiting liver transplantation in the united states. Am J Transplant. 2011;11:1773–1784. - PMC - PubMed
    1. Demetriou AA, Brown RS, Jr, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 2004;239:660–667. discussion 667-670. - PMC - PubMed
    1. Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology. 1996;24:1446–1451. - PubMed
    1. Galili U. Evolution and pathophysiology of the human natural antialpha-galactosyl igg (antigal) antibody. Springer semin immunopathol. 1993;15:155–171. - PubMed
    1. Lai L, Kolber-Simonds D, Park KW, et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science. 2002;295:1089–1092. - PubMed

Publication types